Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agents antinéoplasiques - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agents antinéoplasiques - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - comprimés pelliculés - dasatinibum 20 mg, lactosum monohydricum 27 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.14 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 0.67 mg, e 171, triacetinum, pro compresso obducto. - chromosome philadelphie positive leucémie myéloïde chronique; chromosome philadelphie positif de la leucémie aiguë lymphoblastique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - comprimés pelliculés - dasatinibum 50 mg, lactosum monohydricum 67.5 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.36 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 1.68 mg, e 171, triacetinum, pro compresso obducto. - chromosome philadelphie positive leucémie myéloïde chronique; chromosome philadelphie positif de la leucémie aiguë lymphoblastique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - comprimés pelliculés - dasatinibum 70 mg, lactosum monohydricum 94.5 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.5 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 2.35 mg, e 171, triacetinum, pro compresso obducto. - chromosome philadelphie positive leucémie myéloïde chronique; chromosome philadelphie positif de la leucémie aiguë lymphoblastique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - comprimés pelliculés - dasatinibum 80 mg, lactosum monohydricum 108 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.58 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 2.69 mg, e 171, triacetinum, pro compresso obducto. - chromosome philadelphie positive leucémie myéloïde chronique; chromosome philadelphie positif de la leucémie aiguë lymphoblastique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - comprimés pelliculés - dasatinibum 100 mg, lactosum monohydricum 135 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.72 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 3.36 mg, e 171, triacetinum, pro compresso obducto. - chromosome philadelphie positive leucémie myéloïde chronique; chromosome philadelphie positif de la leucémie aiguë lymphoblastique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - dasatinibum - comprimés pelliculés - dasatinibum 140 mg, lactosum monohydricum 189 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.72 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 4.7 mg, e 171, triacetinum, pro compresso obducto. - chromosome philadelphie positive leucémie myéloïde chronique; chromosome philadelphie positif de la leucémie aiguë lymphoblastique - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - dasatinibum - comprimés pelliculés - filmtablette: dasatinibum 20.00 mg, lactosum monohydricum 27.00 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.14 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 0.67 mg, e 171, triacetinum, pro compresso obducto. - onkologikum - synthetika

Uswisi - Kifaransa - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - dasatinibum - comprimés pelliculés - filmtablette: dasatinibum 50.00 mg, lactosum monohydricum 67.50 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium 0.36 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 1.68 mg, e 171, triacetinum, pro compresso obducto. - onkologikum - synthetika